Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An analysis of blood samples from COVID-19 patients has found that patients with elevated levels of a marker for T cells activity went on to develop only mild symptoms. The study, led by Professor Tao Dong (Radcliffe Department of Medicine) found that patients with lower levels of this marker had more severe symptoms.

© Blausen Medical

T cells are a core part of the body’s adaptive immune response, producing a tailored response to specific antigens. Measuring key biomarkers when patients first get ill might not only predict who will go on to develop mild versus severe illness, but interventions to change these markers might also help prevent severe illness.

Professor Dong, who is also the co-director of the Oxford University’s, Chinese Academy of Medical Science’s Oxford Institute, analysed data from 71 COVID-19 positive patients hospitalised at Beijing’s You’an Hospital in January and March this year.  53 of the patients turned out to have a mild illness, while 18 had more serious symptoms.

Read the full story on the Radcliffe Department of Medicine website

Similar stories

Major grant to strengthen research and benefit patients

Oxford University Hospitals (OUH) has made a grant of £11.5 million to the University of Oxford, which the University will match with other funding, to allow the development of major clinical research facilities which have the potential to support the introduction of innovative and ground-breaking treatments for patients.

Dr Lennard Lee awarded ACP McElwain Prize for contributions to medical oncology

Dr Lee (Department of Oncology) received the award to acknowledge his contributions during the COVID-19 pandemic, through the establishment of the UK Coronavirus Cancer Monitoring Project.

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Ivermectin to be investigated as a possible treatment for COVID-19 in the PRINCIPLE trial

From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.